Target intelligence / Profile preview

Vacuolar ATPase accessory protein

Molecular classification
Enzyme accessory protein, Transporter accessory protein, Other (V-ATPase complex subunit)
01

Overview

Vacuolar ATPase accessory proteins are non-catalytic protein components required for the proper assembly, stability, and function of the vacuolar H^+-ATPase (V-ATPase) complex, a multi-subunit enzyme proton pump responsible for acidifying intracellular organelles and, in some specialized cells, the plasma membrane[6][7]. Key accessory proteins in mammals include ATP6AP1 (Ac45) and ATP6AP2 ((pro)renin receptor or PRR), which are essential for assembling the V-ATPase catalytic (V1) and membrane (V0) sectors and enabling proton translocation across biological membranes[5][6][7]. These accessory proteins are critical modulators of processes such as lysosomal degradation, autophagy, synaptic vesicle function, bone resorption, renal acid–base balance, and antigen processing[4][5][6]. Malfunction or mutations in V-ATPase accessory proteins are implicated in several pathologies, including osteopetrosis, renal tubular acidosis, neurodegeneration, infections, and cancer progression[5][6]. Current therapeutic research focuses on targeting V-ATPase function as a whole rather than its accessory proteins specifically; however, the accessory proteins represent potential future therapeutic targets due to their regulatory roles[5][6][7].

Other names
Ac45 (for ATP6AP1/Ac45)(pro)renin receptor (for ATP6AP2/PRR)V-ATPase accessory proteins
02

Mechanism of action

Modulation of V-ATPase assembly/function, Regulation of proton pumping, Indirect acidification of cellular compartments

03

Biological functions

Regulation of proton pump assembly and functionOrganelle acidificationLysosomal acidificationEndocytosisNeurotransmitter loadingProtein degradationAntigen presentation
04

Disease associations

CancerOsteopetrosisRenal tubular acidosisNeurodegenerative diseaseInfectionMetabolic disease (e.g., diabetes, atherosclerosis)
05

Safety considerations

Broad impact on cellular acid–base homeostasisPotential for toxicity due to global disruption of proton gradientsRisk of off-target organelle dysfunction
06

Interacting drugs

None identified; as of current evidence, there are no FDA-approved drugs specifically targeting V-ATPase accessory proteins, but V-ATPase inhibitors are under investigation
07

Biomarkers

No well-established biomarkers specific to accessory proteins for patient selection or monitoring efficacy

Beyond the preview

Go deeper on Vacuolar ATPase accessory protein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vacuolar ATPase accessory protein.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call